OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
Saad I. Mallah, Abdulla Alawadhi, Jaleela S. Jawad, et al.
Vaccine (2023) Vol. 41, Iss. 12, pp. 1925-1933
Open Access | Times Cited: 22
Saad I. Mallah, Abdulla Alawadhi, Jaleela S. Jawad, et al.
Vaccine (2023) Vol. 41, Iss. 12, pp. 1925-1933
Open Access | Times Cited: 22
Showing 22 citing articles:
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
Charlotte Primard, Élodie Monchâtre-Leroy, Judith del Campo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Charlotte Primard, Élodie Monchâtre-Leroy, Judith del Campo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination
Maaweya Awadalla, Halah Z. AlRawi, Rahaf A. Henawi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Maaweya Awadalla, Halah Z. AlRawi, Rahaf A. Henawi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial
Suad Hannawi, Lixin Yan, Linda Saf Eldin, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102195-102195
Open Access | Times Cited: 17
Suad Hannawi, Lixin Yan, Linda Saf Eldin, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102195-102195
Open Access | Times Cited: 17
Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine
Viravarn Luvira, Punnee Pitisuttithum
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 283-293
Open Access | Times Cited: 4
Viravarn Luvira, Punnee Pitisuttithum
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 283-293
Open Access | Times Cited: 4
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Vaccination Strategies: Mixing Paths Versus Matching Tracks
Achilleas Livieratos, Charalambos Gogos, Ιάσων Θωμάς, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 308-308
Open Access
Achilleas Livieratos, Charalambos Gogos, Ιάσων Θωμάς, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 308-308
Open Access
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials
Gui-Ling Chen, Yuan-zheng Qiu, Kaiqi Wu, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 3
Open Access | Times Cited: 8
Gui-Ling Chen, Yuan-zheng Qiu, Kaiqi Wu, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 3
Open Access | Times Cited: 8
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial
Yu‐Wen Su, Yuan-Zheng Qiu, Yuanhui Wang, et al.
Vaccine (2024) Vol. 42, Iss. 9, pp. 2438-2447
Closed Access | Times Cited: 3
Yu‐Wen Su, Yuan-Zheng Qiu, Yuanhui Wang, et al.
Vaccine (2024) Vol. 42, Iss. 9, pp. 2438-2447
Closed Access | Times Cited: 3
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up
Mohammadreza Salehi, Ilad Alavi Darazam, Alireza Nematollahi, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112192-112192
Closed Access | Times Cited: 3
Mohammadreza Salehi, Ilad Alavi Darazam, Alireza Nematollahi, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112192-112192
Closed Access | Times Cited: 3
Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency
Yanli Song, Jiaolei Wang, Zhihui Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Yanli Song, Jiaolei Wang, Zhihui Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Designing an integrated sustainable-resilient mix-and-match vaccine supply chain network
Ali Jahed, Seyyed Mohammad Hadji Molana, Reza Tavakkoli‐Moghaddam, et al.
Annals of Operations Research (2024)
Closed Access | Times Cited: 3
Ali Jahed, Seyyed Mohammad Hadji Molana, Reza Tavakkoli‐Moghaddam, et al.
Annals of Operations Research (2024)
Closed Access | Times Cited: 3
Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial
Xiaoqiang Liu, Zhonghan Sun, Zhongfang Wang, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102231-102231
Open Access | Times Cited: 7
Xiaoqiang Liu, Zhonghan Sun, Zhongfang Wang, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102231-102231
Open Access | Times Cited: 7
SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost
Olivera Lijeskić, Neda Bauman, Miloš Marković, et al.
Vaccine (2024) Vol. 42, Iss. 7, pp. 1665-1672
Closed Access | Times Cited: 1
Olivera Lijeskić, Neda Bauman, Miloš Marković, et al.
Vaccine (2024) Vol. 42, Iss. 7, pp. 1665-1672
Closed Access | Times Cited: 1
Long‐term immunogenicity and safety of heterologous boosting with a SARS‐CoV‐2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine
Jianying Huang, Yuan-zheng Qiu, Lin Luo, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Closed Access | Times Cited: 1
Jianying Huang, Yuan-zheng Qiu, Lin Luo, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Closed Access | Times Cited: 1
Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster
Jun Liu, Jing Sun, Liping Luo, et al.
Zoonoses (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Jun Liu, Jing Sun, Liping Luo, et al.
Zoonoses (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization
Rima Moghnieh, Wajdi Haddad, Nayla Jbeily, et al.
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0306457-e0306457
Open Access | Times Cited: 1
Rima Moghnieh, Wajdi Haddad, Nayla Jbeily, et al.
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0306457-e0306457
Open Access | Times Cited: 1
Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru
Stephanie Montero, Diego Urrunaga‐Pastor, Percy Soto-Becerra, et al.
Vaccine X (2023) Vol. 14, pp. 100311-100311
Open Access | Times Cited: 3
Stephanie Montero, Diego Urrunaga‐Pastor, Percy Soto-Becerra, et al.
Vaccine X (2023) Vol. 14, pp. 100311-100311
Open Access | Times Cited: 3
Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals
Hanisah Sharif, Hazim Ghani, Liyana Ahmad, et al.
Vaccine (2023) Vol. 41, Iss. 47, pp. 6910-6913
Open Access | Times Cited: 1
Hanisah Sharif, Hazim Ghani, Liyana Ahmad, et al.
Vaccine (2023) Vol. 41, Iss. 47, pp. 6910-6913
Open Access | Times Cited: 1
Vaccine Effectiveness against SARS-CoV-2 Infection during the Circulation of Alpha, Delta, or Omicron Variants: A Retrospective Cohort Study in a Tertiary Hospital in Serbia
Danijela Đurić-Petković, Vesna Šuljagić, Vesna Begović-Kuprešanin, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 211-211
Open Access
Danijela Đurić-Petković, Vesna Šuljagić, Vesna Begović-Kuprešanin, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 211-211
Open Access
Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico
Yanet Ventura-Enríquez, Evelyn Cortina-De la Rosa, Elizabeth Díaz-Padilla, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 551-551
Open Access
Yanet Ventura-Enríquez, Evelyn Cortina-De la Rosa, Elizabeth Díaz-Padilla, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 551-551
Open Access
A sustainable vaccine supply-production-distribution network with heterologous and homologous vaccination strategies: Bi-objective optimization
Ali Jahed, Seyyed Mohammad Hadji Molana, Reza Tavakkoli‐Moghaddam
Socio-Economic Planning Sciences (2024), pp. 102113-102113
Closed Access
Ali Jahed, Seyyed Mohammad Hadji Molana, Reza Tavakkoli‐Moghaddam
Socio-Economic Planning Sciences (2024), pp. 102113-102113
Closed Access
Effect of Homologous and Heterologous Booster in COVID-19 Vaccination
Marija Vukčević, Mateja Despot, Aleksandra Nikolić‐Kokić, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1734-1734
Open Access
Marija Vukčević, Mateja Despot, Aleksandra Nikolić‐Kokić, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1734-1734
Open Access
